With Type 1 Diabetes Delay Possible, Focus Now on Screening

The FDA approval of teplizumab for the delay of type 1 diabetes highlights the need to cost-effectively identify those at risk who could potentially receive it.

Related Keywords

Colorado ,United States ,Germany ,Washington ,United Kingdom ,Denver ,Seattle ,Aaron Kowalski ,Jason Hoitt ,Williama Hagopian ,Provention Bio ,Pacific Northwest Research Institute ,Human Services ,Drug Administration ,Us Department Of Health ,Screening Panel ,Medscape Medical News ,Would Screening ,Western Europe ,Medscape Medical ,Washington State ,Recommended Uniform Screening Panel ,Two Pronged Approach ,Screening Could Work ,Diabetes Mellitus Type 1 ,Iabetes Mellitus Type I ,Type 1 Diabetes ,Preventive Screening ,Screening ,Children ,Child ,Childhood ,Ediatrics ,Kids ,Newborn ,Neonate ,Newborn Screening ,Genetics ,Genomics ,Genomic Medicine ,Edicine Genomic ,Pregnancy ,Human Leukocyte Antigen ,La Human Leukocyte Antigen ,Biologic Therapy ,Immunotherapy ,Monoclonal Antibody ,Etuximab ,Ituximab ,United Kingdom Site Conten ,